NCT01067326View on ClinicalTrials.gov

The Effect of Tekturna on Endothelial Function and Endothelial Progenitor Cells in Patients With Early Atherosclerosis

PHASE3TerminatedINTERVENTIONAL

Enrollment

22

Participants

Timeline

Start Date

February 28, 2010

Primary Completion Date

December 31, 2011

Study Completion Date

December 31, 2011

Conditions

Endothelial Dysfunction

Interventions

DRUG

Aliskiren

150 mg Aliskiren once daily for a period of 4 months

DRUG

Placebo

1 pill per day by mouth for 4 months

Trial Locations (1)

55905

Mayo Clinic in Rochester, Rochester

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors

collaborator

National Institute on Aging (NIA)

NIH

collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

collaborator

Novartis

INDUSTRY

lead

Mayo Clinic

OTHER